Using the two PROTACs (DT2166 and PZ15227) to degrade BCL-XL, we are able to define the critical pro-survival function of BCL-XL within TI-Tregs, which represents a potential method to deplete TI-Tregs for cancer immunotherapy. This evidence concerns the gene BCL2L1 and cancer.